Merus (NASDAQ:MRUS) Rating Reiterated by William Blair

Merus (NASDAQ:MRUS)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a note issued to investors on Monday, RTT News reports.

A number of other brokerages also recently issued reports on MRUS. Needham & Company LLC restated a “buy” rating and set a $66.00 price target on shares of Merus in a report on Thursday, April 11th. StockNews.com downgraded shares of Merus from a “hold” rating to a “sell” rating in a report on Monday, March 4th. BMO Capital Markets raised their price target on shares of Merus from $49.00 to $58.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Stifel Nicolaus raised their price target on shares of Merus from $40.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Finally, Truist Financial initiated coverage on shares of Merus in a report on Thursday, March 28th. They set a “buy” rating and a $69.00 price target for the company. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $56.33.

Merus Price Performance

MRUS opened at $40.82 on Monday. The company’s 50 day simple moving average is $45.05 and its two-hundred day simple moving average is $33.39. Merus has a 1-year low of $18.21 and a 1-year high of $52.03. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of -13.47 and a beta of 1.10.

Merus (NASDAQ:MRUS) last released its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.38). Merus had a negative return on equity of 50.61% and a negative net margin of 352.56%. The business had revenue of $8.94 million during the quarter, compared to analysts’ expectations of $10.43 million. On average, equities analysts anticipate that Merus will post -3.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Merus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC boosted its position in Merus by 37.7% in the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 343 shares during the period. BluePath Capital Management LLC purchased a new position in Merus in the 3rd quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. boosted its position in Merus by 142.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 867 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in Merus in the 1st quarter valued at approximately $72,000. Finally, Tower Research Capital LLC TRC boosted its position in Merus by 64.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 828 shares during the period. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.